Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Novartis Korea and KPWA agreed on margin increase
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 30, 2014 03:57:22
Novartis Korea and Korean Pharmaceutical Wholesalers Association (KPWA) agreed to raise the margin rate for KPWA, sources said on December 28.

Hwang Chi Yup, President of KPWA said, “We discussed the margin increase with Novartis Korea for the pharmaceutical wholesale industry, including Zuellig Korea. The details can’t be disclosed, but they can handle all the issues by themselves.”

Hwang added, “If there is any issue with Novartis Korea, contact us.”

An official of KPWA said, “The latest agreement is meaningful, looking back on the previous conflicts between KPWA and pharmaceutical companies. We hope the latest agreement with Novartis Korea will open a new chapter for both KPWA and multinational drugmakers to survive together.”

KPWA is still negotiating with Pfizer Korea. KPWA had conflicts with Handok and GlaxoSmithKline Korea in the past.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com